Kolexia
Barletta Hugues Gynécologie
Barletta Hugues
Gynécologie
Cabinet libéral
Valence, France
22 Activités
1 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Tumeurs du sein Carcinomes Tumeurs de la trompe de Fallope {{person.topmesh7.name}} {{person.topmesh8.name}} {{person.topmesh9.name}} {{person.topmesh10.name}}

Collaborateurs

Voir plus
Lantheaume Stephane
Lantheaume Stephane
Clinique Pasteur, Guilherand-Granges, France
Floquet Anne
Floquet Anne
Institut Bergonié, Bordeaux, France
Largillier Remy
Largillier Remy
Hp A. Tzanck Mougins Sophia Antipolis, Mougins, France
Savoye Aude-Marie
Savoye Aude-Marie
Institut Godinot, Reims, France

Industries

Voir plus
MSD
4 collaboration(s)
Dernière en 2023
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients.
Frontiers in pharmacology   20 septembre 2021
Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).
European journal of cancer (Oxford, England : 1990)   08 novembre 2020
Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region.
European journal of cancer care   07 septembre 2020
Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019
Surgical management of Low-Grade Serous Carcinoma of the ovary: Results of a multicenter study from The French National Network dedicated to Ovarian Malignant Rare Tumors (TMRO)
European journal of obstetrics, gynecology, and reproductive biology   01 mars 2019
The Personalised Reimbursement Models (Prm): Real World Data Collection to Provide Innovative Pricing Solutions in France
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research   01 octobre 2017
Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC). Part1: the ENCOURAGE cohort of 1158 patients (pts) by GINECO
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
ENCOURAGE: Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy
Essai Clinique (Roche)   15 mars 2016
Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
PloS one   18 juin 2015
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}